Several studies have found genetic anomalies, such as deletions of IKZF1, CDKN2A/2B and PAX5, to adversely affect outcomes in Ph+ ALL, even when treated with dasatinib and blinatumomab [2,24,28]. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.